Video

When to Change Therapy for Atopic Dermatitis

A brief discussion on when it is best to switch therapy while treating patients for atopic dermatitis.

Transcript:

Lawrence Eichenfield, MD: That’s a great segue into the last segment of our discussion, which is a mixture of core questions for us to summarize where we’re at and what we’ve discussed through this session.

Let me start off. Lisa, discuss how and when you decide to make a change in therapy.

Elizabeth Swanson, MD: For me, it’s pretty straightforward. If I can’t get a patient clear or keep them clear, then I’m going to be discussing and encouraging a change because I want to make these patients’ lives better. I want to make them look better, feel better, and do better. If I can’t get them clear or keep them clear, we should try something different. Fortunately, our option list is growing longer by the day.

Lawrence Eichenfield, MD: What else? Are there other times you’d like to make a change in therapy? I’m not big on changing it because someone else already used it. About half the time, people come in and they just haven’t used enough of a medicine. I don’t necessarily write a new script, I just write a more detailed care plan and do volumetric prescribing, where I tell them a certain volume. In all of medicine but especially in dermatology conditions, what’s needed in each room isn’t just walking in, making the diagnosis, and prescribing something. Partially our decision about when to change therapy and how we change therapy is individualized according to what that particular patient might need.

Thank you for watching this HCPLive® Peer Exchange. If you enjoyed the content, please subscribe to the e-newsletters to receive upcoming Peer Exchanges and other great content in your inbox. Thank you.

Transcript edited for clarity.

Related Videos
Discussing FDA Approval of Tapinarof Cream for Atopic Dermatitis, with John Browning, MD
Discussing 140-Week Data on Upadacitinib for Atopic Dermatitis, with Raj Chovatiya, MD, PhD
ADORING Trial Open-Label Extension: Tapinarof Cream 1% Results in Atopic Dermatitis
Linda Stein Gold, MD: Discussing New Phase 3b Data on Lebrikizumab for Atopic Dermatitis
New ‘Level Up’ Data on Upadacitinib (Rinvoq) for Atopic Dermatitis, with Christopher Bunick, MD, PhD
Shawn Kwatra, MD: Making the Connection Between Prurigo Nodularis, Atopic Dermatitis, and Itch
© 2024 MJH Life Sciences

All rights reserved.